• Dual Enzyme-Responsive Zwitterionic Peptide Enhances Cancer

  2026-04-28

  This study introduces a zwitterionic peptide amphiphile that achieves high cancer selectivity via dual enzyme responsiveness and intralysosomal self-assembly. The design leverages distinct enzyme expression in cancer cells to trigger selective peptide assembly and lysosomal disruption, minimizing off-target toxicity and advancing peptide-based chemotherapeutics.

• PTPN2 Modulates STING–STAT3 Axis and Autophagy in Psoriasis

  2026-04-28

  This study identifies PTPN2 as a negative regulator of psoriasis pathology by targeting the STING–STAT3 signaling pathway and promoting autophagy in keratinocytes. Through in vitro and in vivo models, the authors demonstrate that PTPN2 suppresses STAT3 activation, limits inflammation, and restores cellular homeostasis, providing mechanistic insight and a promising translational target for immune-mediated skin disorders.

• Toremifene Citrate: Applied Workflows in Breast Cancer Resea

  2026-04-27

  Toremifene Citrate is a gold-standard oral selective estrogen receptor modulator for dissecting estrogen receptor signaling and inhibiting breast cancer cell proliferation. This article delivers hands-on workflow guidance, troubleshooting, and evidence-based protocol optimizations to empower robust, reproducible research outcomes.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride for Endothelial Inj

  2026-04-27

  5-(N,N-dimethyl)-Amiloride hydrochloride unlocks new precision for dissecting Na+/H+ exchanger signaling in endothelial and cardiac injury models. This guide delivers applied workflows, troubleshooting insights, and protocol parameters, empowering scientists to translate ionic transport inhibition into meaningful advances in sepsis and cardiovascular research.

• L-Glutathione Reduced: Metabolic Redox Control in Cancer Res

  2026-04-26

  Explore how L-Glutathione Reduced enables advanced metabolic redox control and biomarker discovery in cancer research. This article delivers a unique translational perspective, integrating mechanistic insight with practical assay guidance.

• DAPI Solution (1 mg/mL): Precision DNA Staining for Mechanis

  2026-04-25

  Explore the advanced use of DAPI Solution (1 mg/mL) for mechanistic DNA staining in apoptosis, senescence, and cell fate research. This article uniquely bridges fluorescence methodology with recent breakthroughs in macrophage-NP cell interactions using 4',6-Diamidino-2-Phenylindole.

• DAPI Solution (1 mg/mL): Applied Workflows for Nuclear Visua

  2026-04-24

  APExBIO’s DAPI Solution (1 mg/mL) delivers robust, high-contrast nuclear staining for viability assessment and apoptosis detection in fixed or compromised cells. This guide translates state-of-the-art research and hands-on troubleshooting into actionable, reproducible workflows for microscopy and flow cytometry.

• ALT Cancer Cell Sensitivity to ATR Inhibition: A Reassessmen

  2026-04-24

  This study rigorously evaluates whether cancer cells employing the alternative lengthening of telomeres (ALT) pathway exhibit heightened sensitivity to ATR kinase inhibition. Contrary to previous reports, the authors find no general hypersensitivity in ALT-positive cells, highlighting the need for refined assessment of telomere maintenance mechanisms in therapeutic targeting.

• ML385: Selective NRF2 Inhibitor for Cancer and Oxidative Str

  2026-04-23

  ML385 is a selective NRF2 inhibitor with sub-micromolar activity, widely used to dissect NRF2-dependent antioxidant and chemoresistance mechanisms in cancer and metabolic disease models. Robust in vitro and in vivo evidence positions ML385 as a critical tool for evaluating NRF2 signaling pathway inhibition and its impact on therapeutic resistance and ferroptosis.

• Cefodizime: Strategic Leverage in Translational Infection Mo

  2026-04-23

  This article provides translational researchers with a thought-leadership perspective on the mechanistic and strategic positioning of Cefodizime, a third-generation cephalosporin antibiotic. By integrating mechanistic insights, recent resistance surveillance data, and advanced workflow guidance, we delineate how Cefodizime—sourced from APExBIO—can transform infectious disease research, with a special focus on optimizing experimental reproducibility and addressing real-world resistance trends. Drawing on recent findings from psychiatric hospital cohorts and cross-referencing leading workflow articles, this piece delivers actionable recommendations and a visionary outlook for antibiotic innovation.

• BIBR 1532: Selective Telomerase Inhibitor for Cancer Researc

  2026-04-22

  BIBR 1532 is a potent, selective telomerase inhibitor targeting hTERT, validated for telomerase activity assays and cancer cell proliferation inhibition. Its non-nucleosidic structure enables precise modulation of telomerase-driven pathways, making it essential for apoptosis induction studies in leukemia. APExBIO supplies BIBR 1532 in high-purity solid form for advanced oncology research.

• A40926: Dalbavancin Precursor Accelerates MRSA Research

  2026-04-22

  A40926, as a potent dalbavancin precursor, streamlines in vitro antibacterial assays and in vivo infection models targeting Gram-positive pathogens and multidrug-resistant strains like MRSA. Its unique biosynthetic control and robust inhibition profile enable reproducible, high-sensitivity research workflows.

• PDHA1 Succinylation Drives Immune Evasion in Cholangiocarcin

  2026-04-21

  The referenced study uncovers how succinylation of PDHA1 at lysine 83 in cholangiocarcinoma alters tumor metabolism to promote immune escape via alpha-ketoglutaric acid accumulation. Targeting this modification with the mitochondrial inhibitor CPI-613 restores macrophage antigen presentation and sensitizes tumors to chemotherapy, providing a mechanistic rationale for new therapeutic strategies.

• Isradipine (Dynacirc): Precision Modulation for Calcium Over

  2026-04-21

  Explore Isradipine (Dynacirc) as a high-purity, L-type calcium channel antagonist for dissecting calcium overload and neuroprotection in advanced biomedical research. This article uniquely bridges pharmacological selectivity with assay design insights, offering practical guidance for optimizing experimental outcomes.

• Bortezomib (PS-341): Precision Tools for Apoptosis Assays

  2026-04-20

  Bortezomib (PS-341) from APExBIO enables researchers to dissect proteasome-regulated cellular processes with high specificity, driving innovation in apoptosis and cancer biology workflows. This guide translates the latest reference findings into actionable protocols and troubleshooting strategies for reliable, reproducible results.

406 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page